CIRCULOGENE’s OncoGenLDx next generation sequencing (NGS) panel includes NCCN guideline markers, as well as expert recommended actionable mutations across 486 DNA biomarkers and 72 RNA fusions.
The OncoGenLDx NGS panel provides a comprehensive molecular profile to help your doctor prescribe targeted treatment at diagnosis, understand your response to treatment, and monitor cancer progression and recurrence.
CIRCULOGENE offers the ONLY liquid cfRNA PD-L1, Plasma cfRNA PD-L1. Patients with PD-L1 have been known to respond positively to immunotherapy versus chemotherapy. Should you have a PD-L1 expression, your doctor will consider this with other markers and your overall health in order to determine the right treatment for you.
CIRCULOGENE also offers testing for the presence of hereditary genes passed on from parents to offspring. These inherited genes play an important role in cancer risk and susceptibility.
